Featured Publications
VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis.
Kim S, Adams T, Hu Q, Shin H, Chae G, Lee S, Sharma L, Kwon H, Lee F, Park H, Huh W, Manning E, Kaminski N, Sauler M, Chen L, Song J, Kim T, Kang M. VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis. American Journal Of Respiratory Cell And Molecular Biology 2023, 69: 22-33. PMID: 36450109, PMCID: PMC10324045, DOI: 10.1165/rcmb.2022-0219oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisImmune regulatorsTherapeutic potentialHuman idiopathic pulmonary fibrosisCrucial immune regulatorsNovel immune regulatorPulmonary fibrosis micePulmonary fibrosis modelNovel therapeutic targetRole of VISTAWild-type littermatesMonocyte-derived macrophagesT lymphocyte lineageVISTA expressionIPF treatmentAntibody treatmentImmune landscapeFibrotic mediatorsLung fibrosisFibrosis miceInflammatory responseFibrosis modelMyeloid populationsTherapeutic target
2012
MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions
Chandhanayingyong C, Kim Y, Staples JR, Hahn C, Lee FY. MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions. Sarcoma 2012, 2012: 404810. PMID: 22577336, PMCID: PMC3345255, DOI: 10.1155/2012/404810.Peer-Reviewed Original ResearchBone sarcomasClinical trialsEwing's sarcomaLimb salvage surgeryCurrent therapeutic modalitiesRecent clinical trialsMAPK/ERK inhibitorsPromising therapeutic targetHigh-grade chondrosarcomaCytotoxic chemotherapeutic drugsMAPK/ERK signalingSalvage surgeryTherapy regimensClinical benefitMetastatic osteosarcomaInflammatory responseMAPK/ERKClinical dataLocal invasivenessTherapeutic modalitiesCurrent chemotherapyTherapeutic conceptsTherapeutic implicationsTherapeutic targetSarcoma
2011
Actin and ERK1/2-CEBPβ signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells
Lee HG, Minematsu H, Kim KO, Aydemir A, Shin MJ, Nizami SA, Chung KJ, Hsu AC, Jacobs CR, Lee FY. Actin and ERK1/2-CEBPβ signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells. Biomaterials 2011, 32: 9197-9206. PMID: 21899882, PMCID: PMC3193180, DOI: 10.1016/j.biomaterials.2011.08.059.Peer-Reviewed Original ResearchMeSH KeywordsActinsAdhesivenessAnimalsBenzimidazolesBone and BonesCCAAT-Enhancer-Binding Protein-betaCyclooxygenase 2Cytochalasin DExtracellular Signal-Regulated MAP KinasesGene Expression RegulationHumansImmunity, InnateInflammationInterleukin-6MAP Kinase Signaling SystemMiceModels, BiologicalOsteogenesisOsteolysisPhagocytosisProtein Kinase InhibitorsSignal TransductionSkullStem CellsTime FactorsTitaniumConceptsInflammatory osteolysisInflammatory responseMacrophage-mediated inflammatory responsesKey inflammatory pathwaysSuitable therapeutic targetInflammatory gene expressionInnate immune responseOsteoprogenitor cellsInflammatory cascadeInflammatory pathwaysImmune responseTherapeutic targetHost bone-implant interfaceAZD6244 treatmentIntracellular mechanismsBone-implant interfaceBone formationCellular mechanismsERK pathwayInflammationΒ pathwayOsteoclastogenesisOsteolysisIntracellular signalingImplant osteointegration
2010
Surmounting Chemotherapy and Radioresistance in Chondrosarcoma: Molecular Mechanisms and Therapeutic Targets
Onishi AC, Hincker AM, Lee FY. Surmounting Chemotherapy and Radioresistance in Chondrosarcoma: Molecular Mechanisms and Therapeutic Targets. Sarcoma 2010, 2011: 381564. PMID: 21234363, PMCID: PMC3018623, DOI: 10.1155/2011/381564.Peer-Reviewed Original ResearchNature of chemotherapyNew molecular targetsDirected therapyPrimary malignancySurgical resectionRadiation regimensCurative treatmentMolecular mechanismsSuccessful treatmentTherapeutic targetChemotherapyChondrosarcomaMolecular targetsTumorsTherapy researchTreatmentCurrent hypothesesResectionRegimensPatientsMalignancyTherapyDiagnosis
2009
Targeting extracellular signal-regulated kinase (ERK) signaling has therapeutic implications for inflammatory osteolysis
Seo SW, Lee D, Minematsu H, Kim AD, Shin M, Cho SK, Kim DW, Yang J, Lee FY. Targeting extracellular signal-regulated kinase (ERK) signaling has therapeutic implications for inflammatory osteolysis. Bone 2009, 46: 695-702. PMID: 19895919, PMCID: PMC2823832, DOI: 10.1016/j.bone.2009.10.032.Peer-Reviewed Original ResearchConceptsInflammatory osteolysisInflammatory responseInnate immune responseExtracellular signal-regulated kinase (ERK) signalingImportant therapeutic targetM-CSF expressionSignal-regulated kinase 1/2 pathwaySignal-regulated kinase signalingExtracellular signal-regulated kinase 1/2 (ERK1/2) pathwayInhibition of ERKImmune responseTherapeutic implicationsTherapeutic targetOsteoclast precursorsKinase 1/2 pathwayM-CSFOsteolysisERK pathwayMacrophage colonyLPSERKERK signalsMitogen-activated protein kinase (MAPK) familyKinase signalingCell differentiation